Efficacy of belimumab for the long-term maintenance therapy of thrombocytopenia in systemic lupus erythematosus

Clin Exp Rheumatol. 2017 Nov-Dec;35(6):1056. Epub 2017 Jul 26.

Authors

Ginevra De Marchi¹, Luca Quartuccio¹, Milena Bond¹, Salvatore De Vita²

Affiliations

¹ Rheumatology Clinic, Department of Medical and Biological Sciences, Azienda Ospedaliero-Universitaria 'S. Maria della Misericordia', Udine, Italy.
² Rheumatology Clinic, Department of Medical and Biological Sciences, Azienda Ospedaliero-Universitaria 'S. Maria della Misericordia', Udine, Italy. salvatore.devita@asuiud.sanita.fvg.it.

PMID: 28770706

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
B-Cell Activating Factor / antagonists & inhibitors
Female
Humans
Immunoglobulins, Intravenous / therapeutic use
Immunosuppressive Agents / therapeutic use*
Lupus Erythematosus, Systemic / complications
Lupus Erythematosus, Systemic / drug therapy*
Thrombocytopenia / drug therapy*
Thrombocytopenia / etiology

Substances

Antibodies, Monoclonal, Humanized
B-Cell Activating Factor
Immunoglobulins, Intravenous
Immunosuppressive Agents
TNFSF13B protein, human
belimumab